{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
GE Healthcare Technologies, Inc.
Is GE Healthcare Technologies, Inc. overvalued or undervalued?
As of November 14, 2025, GE Healthcare Technologies, Inc. has shifted from a very attractive to an attractive valuation grade, appearing overvalued with a P/E ratio of 14 and a high Price to Book Value of 3.57, despite a low PEG ratio of 0.39, and has underperformed the S&P 500 with a year-to-date return of -6.43%.
Is GE Healthcare Technologies, Inc. overvalued or undervalued?
As of November 14, 2025, GE Healthcare Technologies, Inc. is considered fairly valued with a P/E ratio of 14 and lower than its peers, but has underperformed with a year-to-date return of -6.43% compared to the S&P 500's 14.49%.
Is GE Healthcare Technologies, Inc. overvalued or undervalued?
As of November 7, 2025, GE Healthcare Technologies, Inc. is considered a very attractive investment due to its undervalued status reflected in favorable P/E, PEG, and EV to EBITDA ratios, despite a challenging year with a -14.5% stock return.
Is GE Healthcare Technologies, Inc. overvalued or undervalued?
As of November 7, 2025, GE Healthcare Technologies, Inc. is considered very attractive due to its undervalued status indicated by favorable P/E, PEG, and EV to EBITDA ratios compared to peers, despite underperforming the S&P 500 with a year-to-date return of -6.56%.
Is GE Healthcare Technologies, Inc. overvalued or undervalued?
As of November 7, 2025, GE Healthcare Technologies, Inc. is considered very attractive due to its undervalued status, with a P/E ratio of 14, an EV to EBITDA of 11.16, a PEG ratio of 0.39, and strong ROE and ROCE metrics, despite recent stock underperformance compared to the S&P 500.
Is GE Healthcare Technologies, Inc. overvalued or undervalued?
As of October 17, 2025, GE Healthcare Technologies, Inc. is considered very attractive and undervalued, with a P/E ratio of 14, a PEG ratio of 0.39, and strong operational efficiency metrics, despite a recent stock decline of 18.47%.
GE Healthcare Technologies, Inc. Experiences Valuation Adjustment Amid Strong Financial Metrics
GE Healthcare Technologies, Inc. has adjusted its valuation, showcasing strong financial metrics in the Pharmaceuticals & Biotechnology sector. With a favorable P/E ratio and solid operational efficiency, the company demonstrates impressive profitability through high returns on capital and equity, positioning it competitively against industry peers.
GE Healthcare Technologies Experiences Revision in Stock Evaluation Amid Mixed Market Signals
GE Healthcare Technologies, Inc. has recently revised its evaluation amid fluctuating market conditions. The stock, currently priced at $74.05, has shown volatility over the past year, with a high of $94.80 and a low of $57.65. Performance metrics indicate mixed technical signals and challenges in aligning with broader market trends.
Is GE Healthcare Technologies, Inc. overvalued or undervalued?
As of October 17, 2025, GE Healthcare Technologies, Inc. is considered very attractive in valuation due to its low P/E ratio of 14 and PEG ratio of 0.39, indicating it is undervalued compared to peers like Edwards Lifesciences and Agilent Technologies.
Is GE Healthcare Technologies, Inc. overvalued or undervalued?
As of October 17, 2025, GE Healthcare Technologies, Inc. is considered a very attractive investment due to its undervalued metrics, including a P/E ratio of 14 and strong profitability indicators, despite recent challenges.
Is GE Healthcare Technologies, Inc. technically bullish or bearish?
As of September 12, 2025, GE Healthcare Technologies, Inc. shows a mildly bearish trend with underperformance against the S&P 500, indicated by bearish moving averages and mixed MACD signals.
GE Healthcare Technologies Experiences Revision in Stock Evaluation Amid Mixed Performance Indicators
GE Healthcare Technologies, Inc. has experienced a technical trend adjustment, with its stock price at $77.76. Over the past year, the company has faced challenges, posting a return of -10.53%, significantly underperforming the S&P 500. Mixed technical indicators suggest volatility and a need for ongoing performance monitoring.
GE Healthcare Technologies Experiences Revision in Stock Evaluation Amid Mixed Performance Indicators
GE Healthcare Technologies, Inc. has experienced a technical trend adjustment, with its stock price at $77.76. Over the past year, the company has faced challenges, posting a return of -10.53%, significantly underperforming the S&P 500. Mixed technical indicators suggest volatility and a need for ongoing performance monitoring.
Is GE Healthcare Technologies, Inc. overvalued or undervalued?
As of April 30, 2025, GE Healthcare Technologies, Inc. is considered an attractive investment opportunity due to its undervaluation with a P/E ratio of 14, strong ROE of 25.79%, and a current price of 71.16, despite a year-to-date decline of -8.98%.
Is GE Healthcare Technologies, Inc. technically bullish or bearish?
As of June 3, 2025, GE Healthcare Technologies, Inc. shows a mildly bearish trend due to mixed technical indicators, with bearish signals outweighing a mildly bullish MACD.
What does GE Healthcare Technologies, Inc. do?
GE Healthcare Technologies, Inc. is a large-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $4.777 billion and a net profit of $588 million. It has a market cap of approximately $32.57 billion, a P/E ratio of 14.00, and a return on equity of 25.79%.
How big is GE Healthcare Technologies, Inc.?
As of Jun 18, GE Healthcare Technologies, Inc. has a market capitalization of $32.57 billion, with net sales of $19.80 billion and a net profit of $2.25 billion over the latest four quarters. The company reports shareholder's funds of $8.45 billion and total assets of $33.09 billion.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
